Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3Genitourinary 3Gastrointestinal 3Thoracic 2Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 19Paclitaxel 6Trastuzumab 5Nivolumab 5palbociclib 4Carboplatin 4Biopsy 4lenvatinib 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Immunoglobulin G 3Fulvestrant 3Cyclophosphamide 3Cetuximab 3trastuzumab deruxtecan 2tisotumab vedotin 2spartalizumab 2sargramostim 2gedatolisib 2fludarabine 2epacadostat 2capivasertib 2X-Rays 2Sunitinib 2Docetaxel 2Disulfides 2Cisplatin 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × tisotumab vedotin × Head & Neck × Clear all
NCT02001623 2021-12-29

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

Phase 1/2 Completed
195 enrolled 51 charts
GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03245736 2021-11-04

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen Inc.

Phase 2 Completed
5 enrolled 8 charts
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡